Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis c Clear all

Conditions: Hepatitis C, Chronic
Interventions: Interleukin 28B testing; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 4,766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Alexandria, Virginia

Conditions: Genotype 1 Chronic Hepatitis C
Interventions: GI-5005, Pegylated Interferon and Ribavirin; Drug
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more

Conditions: Human Immunodeficiency Virus (HIV), Hepatitis C (HCV)
Interventions: Video Format with Captions, Video Format without Captions, Health Educator; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Hepatitis C
Interventions: BMS-790052, BMS-650032, Pegylated-interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 10
States / cities: Anaheim, California • Coronado, California • San Jose, California + 7 more

Conditions: Hepatitis C, Thalassemia
Interventions: Peginterferon Alfa-2a and Ribavirin, Ribavirin; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 18 Years to 44 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 3
States / cities: Oakland, California • New York, New York • Philadelphia, Pennsylvania

Conditions: Hepatitis C, HIV Infections, Opioid-use Disorder
Interventions: PRC brief motivational interview intervention, Phone contact; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HCV Infection
Interventions: Voxilaprevir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Conditions: Hepatitis C
Interventions: Pegylated Interferon Lambda, Ribasphere, Daclatasvir; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C, Liver Diseases
Interventions: Patient portal message; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 54 Years to 74 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Alcoholism, Cirrhosis, Hepatitis c
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 20 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Human Immunodeficiency Virus Infection, Hepatitis C
Interventions: Not listed
Lead sponsor: G & W Laboratories Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Fort Lauderdale, Florida • Douglasville, Georgia • Baltimore, Maryland + 1 more

Conditions: Hepatitis C
Interventions: VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more

Conditions: HIV, Hepatitis C, Hepatitis B, Syphilis
Interventions: Rapid tests for HIV, HCV, HBV, and syphilis, HIV/HCV, HIV/syphilis, HIV only; Device
Lead sponsor: California State University, Long Beach; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Long Beach, California

Conditions: HCV Infection
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C
Interventions: Patient-Centered Electronic App; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Coinfection
Interventions: Maraviroc, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 24
States / cities: Bakersfield, California • Los Angeles, California • Oakland, California + 16 more

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 38
States / cities: Little Rock, Arkansas • Los Angeles, California • Pasadena, California + 31 more

Conditions: Hepatitis C, HIV
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Treatment of Hepatitis C
Interventions: Ledipasvir/Sofosbuvir FDC; Drug
Lead sponsor: Peter J. Ruane, M.D., Inc.; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Hepatitis C
Interventions: NM283 plus Peg-IFNα-2a; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 114 participants
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Atlanta, Georgia • Fairfax, Virginia

Conditions: Cancer
Interventions: Not listed
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 3,051 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 58
States / cities: Fontana, California • Harbor City, California • Martinez, California + 42 more

Conditions: HIV Infections, Hepatitis C
Interventions: Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 24
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Chronic Hepatitis C
Interventions: Gamma Interferon 1b; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C Virus, HCV Infection, Chronic HCV, Hepatitis C
Interventions: Naringenin; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

Persuasive Health Communication Intervention for HIV/HCV

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

Coaching for HCV and HIV

Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Electronic Record Assimilation and Subsequent Eradication of Hepatitis C

Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound

Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

Behavioral Science Aspects of Rapid Test Acceptance

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)

Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

S1204, Viral Screening in Newly Diagnosed Cancer Patients

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

Gamma Interferon Therapy for Chronic Hepatitis C

A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection